GILEAD SCIENCES, INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
GILEAD SCIENCES, INC. (GILD) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $75.00 million for the 1-month period ending 2017-10-31, per its 10-K filed 2020-02-25.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2020-02-25
- 2017-10-31: Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month $75.00M.
- 2017-10-03: Business Combination, Consideration Transferred, Equity Interests Issued and Issuable $75.00M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month |
|---|---|---|
| 2017-10-31 | $75.00M 10-K · filed 2020-02-25 | |
| 2017-10-03 | $75.00M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |